ABBV vs ONC
AbbVie Inc. (ABBV) and BeOne Medicines Ltd. (ONC) are both filed with the SEC under Pharmaceutical Preparations. ONC is 1.2× ABBV's size by market cap ($550.6B against $456.2B); ONC trades at the higher fiscal-year P/E (1960.5× against 109.4×); ABBV reports the higher net margin (6.9% against 5.4%); ONC grew sales faster over three years (+55.7% against +1.8%); and over the past year ABBV returned +25.8% against ONC's +23.1%.
| ABBV | ONC | |
|---|---|---|
| Last close | $255.48 | $366.73 |
| Market cap | $456.2B | $550.6B |
| P/E (FY) | 109.4× | 1960.5× |
| P/S | 7.5× | 103.0× |
| EV/EBITDA | — | 929.1× |
| Gross margin | — | 87.5% |
| Operating margin | 24.6% | 8.4% |
| Net margin | 6.9% | 5.4% |
| Return on equity | — | 7.5% |
| Sales growth (3y) | +1.8% | +55.7% |
| EPS growth (3y) | -29.1% | — |
| Dividend yield | 2.6% | — |
| 1-year return | +25.8% | +23.1% |
Screener snapshot — prices as of 2026-08-28. Each side's last close is the most recent session the snapshot holds for that company, which can be an earlier one, and its 1-year return is measured to that close. Market caps struck on 2026-08-27. Last close, market cap and the 1-year return are price figures; every other row is computed over the company's latest filed fiscal year — FY2025 (ended 2025-12-31) for both. — not published for this company. A ratio goes unpublished for more than one reason: a component the calculation needs is not on file, the filing does not tag the line it is read from, or the calculation is not defined on the filed basis — EV/EBITDA is not printed on non-positive EBITDA, and return on equity is not computed on a zero or negative equity base.
Who holds them, and who has traded them
| ABBV | ONC | |
|---|---|---|
| Institutional holders (13F) | 4,044 | 280 |
| Insider buyers − sellers (180d) | -2 | -5 |
| Congressional trades disclosed (180d) | 2 | 0 |
| Executive-branch officials on file — trades disclosed (180d) | 17 | 0 |
Counts only. The congressional figures count transactions dated in the trailing 180 days and disclosed in STOCK Act periodic transaction reports; amounts are filed as ranges and are never summed. The executive-branch figures count the same window of transactions, and they are scoped to one roster. The officials OGE posts for direct download. Insider buyers − sellers counts distinct people filing open-market Form 4 purchases minus distinct people filing open-market sales over the trailing 180 days, capped at ±5.
ABBV vs ONC: common questions
- Is ABBV bigger than ONC?
- ONC carries the larger market cap — $550.6B against $456.2B, both struck on 2026-08-27.
- Which trades at a higher P/E, ABBV or ONC?
- ONC, at a fiscal-year 1960.5× against 109.4× for ABBV. Both are price ÷ latest full-year diluted earnings per share, not a trailing-twelve-month P/E.
- How have ABBV and ONC performed over the past year?
- ABBV returned +25.8% and ONC +23.1%, measured on the trailing calendar year to the last close.
- How many institutions hold ABBV and ONC?
- 4,044 13F filers report a position in ABBV and 280 in ONC, on the latest quarter in the panel.
- Are ABBV and ONC in the same industry?
- Both are filed with the SEC under Pharmaceutical Preparations, which is the classification this pairing is built on.
ABBV overview → · ONC overview → · ABBV institutional ownership → · ONC institutional ownership → · Congress and ABBV → · Executive branch and ABBV →
More in Pharmaceutical Preparations: ABBV vs ABT · ABBV vs REGN · ABBV vs TEVA · ABBV vs VRTX
Stock comparisons lists every pair this site publishes.
Source: SPZCO — https://spzco.com/vs/abbv-vs-onc